Tate & Lyle partners with Zymtronix to leverage novel enzyme immobilization technologies

| Filed in:

4 February 2020 – Ithaca, NY and London, UK – Zymtronix, developer of revolutionary enzyme immobilization technologies, and Tate & Lyle PLC (Tate & Lyle), today announced a new partnership. This partnership includes an investment by Tate & Lyle in Zymtronix’s cutting edge enzyme immobilization platform that will enable the US-based company to drastically scale up its production.

Tate & Lyle logo

Zymtronix’s enzyme immobilization platform helps to transform ingredient manufacturing by improving the productivity of biocatalysis. This is achieved through the immobilization of enzymes onto magnetic metamaterials to increase the efficiency and sustainability of enzyme-based industrial processes. The technology, originating from Cornell University (Ithaca, NY), has broad applications in the food & beverage, flavour & fragrances, pharmaceutical, chemical and agricultural industries. Tate & Lyle’s investment in Zymtronix will enable the company to improve and innovate upon their technology, with the goal of scaling up their platform to support process scale production. Zymtronix is initially working with Tate & Lyle to improve the use of enzymes in the production of certain ingredients and improve cost efficiency.

The two companies were brought together at Rabobank’s TERRA Accelerator 2019 in San Francisco, US. As part of the partnership, the retired Chief Technology Officer of Tate & Lyle, Michael Harrison, will join the board of Zymtronix, aiding the company with his wealth of experience within the food and beverage ingredients market.

“Consumers worldwide are looking for healthier food and drink, and we are proud to have the ingredients to help deliver just that. Improving lives for generations is at the heart of what we do, so we are excited to harness the power of Zymtronix’s enzyme immobilization platform, which will make our manufacturing processes more efficient. The platform also has the potential to accelerate our ability to make our ingredient solutions accessible to more consumers,” said Andrew Taylor, President of Innovation and Commercial Development, Tate & Lyle.

“We are delighted to announce Tate & Lyle as our first corporate partner. Their investment will enable us to further scale up our enzyme immobilization technology, advance our processes, develop our own target ingredients, and grow our team,” said Stéphane Corgié, Founder and CEO-CTO, Zymtronix.


Media Enquiries

Zymtronix:
Sophie Mullany
Notch Communications
[email protected]

Tate & Lyle PLC:+44 (0) 161 457 7230

Anna Taylor,
Corporate Communications Manager,
[email protected]

 


About Zymtronix

Zymtronix Catalytic Systems, Inc. (DBA Zymtronix, Inc.) is a biotech company formed in 2013 as a spin-off out of Cornell University. The company’s unique enzyme immobilization platform can improve any biocatalytic reaction involving single enzymes or multiple enzyme systems. The adaptable technology allows Zymtronix to offer solutions to various industries, including the production of food & beverage ingredients, flavor & fragrance, active pharmaceutical ingredients & fine chemicals. The founder, Stéphane Corgié, PhD (CEO-CTO) is joined by a dedicated and growing team of over 10 employees.

For more information about Zymtronix, please visit www.zymtronix.com  or follow Zymtronix on Twitter or LinkedIn.

Click here for our press image gallery

About Tate & Lyle: 
Tate & Lyle PLC is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, mouthfeel and fibre fortification, our Food & Beverage Solutions business develops solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings. Our Primary Products business produces nutritive sweeteners, industrial starches used in paper and packaging, acidulants and products used for animal nutrition.

We have around 4,400 employees working in more than 60 locations across 30 countries. Tate & Lyle’s purpose is Improving Lives for Generations and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2021, Tate & Lyle sales totalled £2.8 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on TwitterLinkedin or Facebook.